{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:48:22Z","timestamp":1777715302669,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03156-6","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:25:06Z","timestamp":1774880706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"\u00d3scar","family":"Moreno-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tejera-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Leiva-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Santacruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"S\u00e1nchez-Ortiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Arrarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Climent-Grana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ger\u00f3nima","family":"Riera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Lopez-Mondejar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Guillen-Morote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Rold\u00e1n-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"S\u00e1nchez-Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel Luis","family":"Abad-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pico-Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Serrano-Gotarredona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"12","key":"3156_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41574-025-01170-4","volume":"21","author":"YH Lee","year":"2025","unstructured":"Lee YH, Lim S, Davies MJ. Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 Inhibitors. Nat Rev Endocrinol. 2025;21(12):783\u201398. https:\/\/doi.org\/10.1038\/s41574-025-01170-4.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"3156_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"3156_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae039","volume":"17","author":"O Moreno-P\u00e9rez","year":"2024","unstructured":"Moreno-P\u00e9rez O, Reyes-Garc\u00eda R, Modrego-Pardo I, L\u00f3pez-Mart\u00ednez M, Soler MJ. Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease? Clin Kidney J. 2024;17(4):sfae039. https:\/\/doi.org\/10.1093\/ckj\/sfae039.","journal-title":"Clin Kidney J"},{"issue":"Supplement_1","key":"3156_CR4","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S183\u2013215. https:\/\/doi.org\/10.2337\/dc26-S009.","journal-title":"Diabetes Care"},{"issue":"3","key":"3156_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"issue":"1","key":"3156_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jdi.13093","volume":"11","author":"N Fushimi","year":"2020","unstructured":"Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A. Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients. J Diabetes Investig. 2020;11(1):125\u201331. https:\/\/doi.org\/10.1111\/jdi.13093.","journal-title":"J Diabetes Investig"},{"issue":"4","key":"3156_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/dom.13927","volume":"22","author":"AH Hulst","year":"2020","unstructured":"Hulst AH, Visscher MJ, Godfried MB, et al. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial. Diabetes Obes Metab. 2020;22(4):557\u201365. https:\/\/doi.org\/10.1111\/dom.13927.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"3156_CR8","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.2337\/dci22-0039","volume":"45","author":"K Dhatariya","year":"2022","unstructured":"Dhatariya K. Initiation and continuation of Sodium-Glucose Cotransporter 2 Inhibitors in hospital inpatients: Ready for prime time? Diabetes Care. 2022;45(12):2806\u20137. https:\/\/doi.org\/10.2337\/dci22-0039.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"3156_CR9","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.2337\/dc26-S016","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 16. Diabetes care in the hospital: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S339\u201355. https:\/\/doi.org\/10.2337\/dc26-S016.","journal-title":"Diabetes Care"},{"issue":"12","key":"3156_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41574-025-01157-1","volume":"21","author":"T Idrees","year":"2025","unstructured":"Idrees T, Castro-Revoredo I, Dhatariya KK, Hernandez L, Umpierrez GE. Advances in the management of hyperglycaemia and diabetes mellitus during hospitalization. Nat Rev Endocrinol. 2025;21(12):757\u201368. https:\/\/doi.org\/10.1038\/s41574-025-01157-1.","journal-title":"Nat Rev Endocrinol"},{"issue":"20","key":"3156_CR11","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"5","key":"3156_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489\u201395. https:\/\/doi.org\/10.1503\/cmaj.050051.","journal-title":"CMAJ"},{"issue":"Supplement_1","key":"3156_CR13","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc26-S006","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S132\u201349. https:\/\/doi.org\/10.2337\/dc26-S006.","journal-title":"Diabetes Care"},{"key":"3156_CR14","unstructured":"Fingar KR, Reid LD. Diabetes-Related Inpatient Stays, 2018. In: healthcare cost and utilization project (HCUP) statistical briefs. Agency for Healthcare Research and Quality (US); 2006. Accessed December 7, 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573775\/"},{"issue":"10","key":"3156_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.eprac.2025.06.014","volume":"31","author":"M Fayfman","year":"2025","unstructured":"Fayfman M, Hochberg I, Magee M, et al. A real-world study of oral antihyperglycemic agents as compared with basal insulin in hospitalized patients with Type 2 Diabetes. Endocr Pract. 2025;31(10):1239\u201346. https:\/\/doi.org\/10.1016\/j.eprac.2025.06.014.","journal-title":"Endocr Pract"},{"issue":"6","key":"3156_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2337\/dc23-1129","volume":"47","author":"LG Singh","year":"2024","unstructured":"Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of continued use of SGLT2 inhibitors from the ambulatory to inpatient setting with hospital outcomes in patients with diabetes: a nationwide cohort study. Diabetes Care. 2024;47(6):933\u201340. https:\/\/doi.org\/10.2337\/dc23-1129.","journal-title":"Diabetes Care"},{"issue":"4","key":"3156_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2337\/dc24-2510","volume":"48","author":"LM Wilson","year":"2025","unstructured":"Wilson LM, Herzig SJ, Marcantonio ER, et al. Management of diabetes and hyperglycemia in the hospital: a systematic review of clinical practice guidelines. Diabetes Care. 2025;48(4):655\u201364. https:\/\/doi.org\/10.2337\/dc24-2510.","journal-title":"Diabetes Care"},{"issue":"8","key":"3156_CR18","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","volume":"107","author":"MT Korytkowski","year":"2022","unstructured":"Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2022;107(8):2101\u201328. https:\/\/doi.org\/10.1210\/clinem\/dgac278.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3156_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eprac.2023.11.014","volume":"30","author":"B Cohen","year":"2024","unstructured":"Cohen B, Harris YT, Schulman-Rosenbaum R. Sodium-glucose cotransporter 2 inhibitors should be avoided for the inpatient management of hyperglycemia. Endocr Pract. 2024;30(4):402\u20138. https:\/\/doi.org\/10.1016\/j.eprac.2023.11.014.","journal-title":"Endocr Pract"},{"issue":"2","key":"3156_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae229","volume":"9","author":"H Fried","year":"2025","unstructured":"Fried H, Harris YT, Schulman-Rosenbaum R. Pros and cons of inpatient SGLT2i use for hyperglycemia and heart failure. J Endocr Soc. 2025;9(2):bvae229. https:\/\/doi.org\/10.1210\/jendso\/bvae229.","journal-title":"J Endocr Soc"},{"issue":"12","key":"3156_CR21","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2337\/dc24-0946","volume":"47","author":"FM Gao","year":"2024","unstructured":"Gao FM, Ali AS, Bellomo R, et al. A systematic review and meta-analysis on the safety and efficacy of sodium-glucose cotransporter 2 inhibitor use in hospitalized patients. Diabetes Care. 2024;47(12):2275\u201390. https:\/\/doi.org\/10.2337\/dc24-0946.","journal-title":"Diabetes Care"},{"issue":"1","key":"3156_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01418-z","volume":"20","author":"J Koska","year":"2021","unstructured":"Koska J, Nuyujukian DS, Bahn GD, Zhou JJ, Reaven PD. Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT). Cardiovasc Diabetol. 2021;20(1):232. https:\/\/doi.org\/10.1186\/s12933-021-01418-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3156_CR23","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.m146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-156. https:\/\/doi.org\/10.1093\/gerona\/56.3.m146.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"3156_CR24","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1093\/gerona\/glad075","volume":"78","author":"PT Htoo","year":"2023","unstructured":"Htoo PT, Paik JM, Alt E, et al. Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk. J Gerontol A Biol Sci Med Sci. 2023;78(12):2426\u201334. https:\/\/doi.org\/10.1093\/gerona\/glad075.","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03156-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:14:45Z","timestamp":1777457685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03156-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. The protocol was reviewed and approved by the Ethics Committee of the Dr Balmis General University Hospital (ref. 2022\u2013054). Given the pragmatic observational design and the use of routinely collected anonymised clinical data, the requirement for written informed consent was waived by the Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}